The TP53 mutations were present years before disease progression and were associated with an increased risk of evolution to AML.42 These findings indicate the existing heterogeneity even within an MDS subtype harboring a single cytogenetic abnormality. The gene discussed is TP53; the disease is myelodysplastic syndrome.